CoChat

Long-term treatment with a glucagon-like peptide-1 receptor agonist reduces ethanol intake in male and female rats

Open access
Vallöf, Daniel, Kalafateli, Aimilia Lydia, Jerlhag, Elisabet · 2020 · Translational Psychiatry
Cited by 72

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Given the limited efficacy of available pharmacotherapies for treatment of alcohol use disorder (AUD), the need for new medications is substantial. Preclinical studies have shown that acute administration of glucagon-like peptide-1 receptor (GLP-1R) agonists inhibits various ethanol-related behaviours, indicating this system as a potential target for AUD. However, the effects of long-term systemic treatment of GLP-1R agonists on ethanol intake in male and female rodents are to date unknown. Therefore, we investigated the effects of 9 or 5 weeks of once weekly administration of dulaglutide, a long-acting GLP-1R agonist, on ethanol intake in male and female rats. The ethanol intake during treatment discontinuation was also monitored. In an initial attempt to identify preliminary underlying mechanisms, the effects of 9 weeks of once weekly dulaglutide treatment on monoaminergic signalling in reward-related areas were explored in both sexes. We found that 9 or 5 weeks of once weekly dulaglutide treatment reduced ethanol intake and preference in male and female rats. Following discontinuation of dulaglutide treatment, the decrease in ethanol consumption was prolonged in males, but not females. We demonstrated that 9 weeks of dulaglutide treatment differentially influenced monoaminergic signalling in reward-related areas of male and female rats. Collectively, these data imply that the GLP-1R attracts interest as a potential molecular target in the medical treatment of AUD in humans: more specifically, dulaglutide should be evaluated as a potential medication for treatment thereof.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41398-020-00923-1

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 33

  1. Naglich, A. C., Lin, A., Wakhlu, S. & Adinoff, B. H. Systematic review of combined pharmacotherapy for the treatment of alcohol use disorder in patients without comorbid conditions. CNS drugs 32, 13–31 (2018). · DOI
  2. Akbar, M. et al. Medications for alcohol use disorders: an overview. Pharmacol. Therapeutics. 185, 64–85 (2018). · DOI · Paper page
  3. Jerlhag, E. Gut-brain axis and addictive disorders: a review with focus on alcohol and drugs of abuse. Pharm. Ther. 196, 1–14 (2019). · DOI · Paper page
  4. Farokhnia, M. et al. Ghrelin: from a gut hormone to a potential therapeutic target for alcohol use disorder. Physiol. Behav. 204, 49–57 (2019). · DOI · Paper page
  5. Holst, J. J. The physiology of glucagon-like peptide 1. Physiol. Rev. 87, 1409–1439 (2007). · DOI · Paper page
  6. Glaesner, W. et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab. Res. Rev. 26, 287–296 (2010). · DOI · Paper page
  7. Shirazi, R. H., Dickson, S. L. & Skibicka, K. P. Gut peptide GLP-1 and its analogue, Exendin-4, decrease alcohol intake and reward. PLoS ONE 8, e61965 (2013). · DOI · Paper page
  8. Thomsen, M. et al. The glucagon-like peptide 1 receptor agonist exendin-4 decreases relapse-like drinking in socially housed mice. Pharm. Biochem. Behav. 160, 14–20 (2017). · DOI
  9. Vallof, D. et al. The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents. Addict. Biol. 21, 422–437 (2016). · DOI · Paper page
  10. Smith, L. L. et al. Dulaglutide (Trulicity): the third once-weekly GLP-1 agonist. P T: Peer-Reviewed J. Formul. Manag. 41, 357–360 (2016).
  11. Usborne, A. et al. An Investigative study of pancreatic exocrine biomarkers, histology, and histomorphometry in Male Zucker Diabetic Fatty (ZDF) rats given dulaglutide by subcutaneous injection twice weekly for 13 weeks. Toxicol. Pathol. 43, 1093–1102 (2015). · DOI
  12. Simms, J. A. et al. Intermittent access to 20% ethanol induces high ethanol consumption in Long-Evans and Wistar rats. Alcohol Clin. Exp. Res. 32, 1816–1823 (2008). · DOI · Paper page
  13. Prieto-Garcia, L. et al. Ghrelin and GHS-R1A signaling within the ventral and laterodorsal tegmental area regulate sexual behavior in sexually naive male mice. Psychoneuroendocrinology 62, 392–402 (2015). · DOI
  14. Sorensen, G., Caine, S. B. & Thomsen, M. Effects of the GLP-1 agonist exendin-4 on intravenous ethanol self-administration in mice. Alcohol Clin. Exp. Res. 40, 2247–2252 (2016). · DOI
  15. Thomsen, M. et al. Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys. Psychopharmacology (Berl.) 236, 603–611 (2018). · DOI · Paper page
  16. Ramchandani, V. A. et al. A genetic determinant of the striatal dopamine response to alcohol in men. Mol. Psychiatry 16, 809–817 (2011). · DOI · Paper page
  17. Yoder, K. K. et al. Heterogeneous effects of alcohol on dopamine release in the striatum: a PET study. Alcohol Clin. Exp. Res. 31, 965–973 (2007). · DOI · Paper page
  18. Yoshimoto, K. et al. Alcohol enhances characteristic releases of dopamine and serotonin in the central nucleus of the amygdala. Neurochemistry Int. 37, 369–376 (2000). · DOI
  19. Engel, J. A. et al. Biochemical and behavioral evidence for an interaction between ethanol and calcium channel antagonists. J. Neural Transm. 74, 181–193 (1988). · DOI
  20. Weiss, F., Lorang, M. T., Bloom, F. E. & Koob, G. F. Oral alcohol self-administration stimulates dopamine release in the rat nucleus accumbens: genetic and motivational determinants. J. Pharm. Exp. Ther. 267, 250–258 (1993).
  21. Wise, R. A. & Bozarth, M. A. Brain mechanisms of drug reward and euphoria. Psychiatr. Med. 3, 445–460 (1985).
  22. Leggio, B. et al. Sardinian alcohol-preferring and non-preferring rats show different reactivity to aversive stimuli and a similar response to a natural reward. Brain Res. 973, 275–284 (2003). · DOI
  23. Wise, R. A. & McDevitt, R. A. Drive and reinforcement circuitry in the brain: origins, neurotransmitters, and projection fields. Neuropsychopharmacology 43, 680–689 (2018). · DOI
  24. Umpierrez, G. E. et al. Lack of lipotoxicity effect on {beta}-cell dysfunction in ketosis-prone type 2 diabetes. Diabetes Care. 33, 626–631 (2010). · DOI
  25. Raun, K. et al. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 56, 8–15 (2007). · DOI · Paper page
  26. Lopez-Ferreras, L. et al. Lateral hypothalamic GLP-1 receptors are critical for the control of food reinforcement, ingestive behavior and body weight. Mol. Psychiatry 23, 1157–1168 (2018). · DOI · Paper page
  27. Gu, G. et al. Glucagon-like peptide-1 in the rat brain: distribution of expression and functional implication. J. Comp. Neurol. 521, 2235–2261 (2013). · DOI · Paper page
  28. Milicevic, Z. et al. Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide. Diabetes Obes. Metab. 18, 533–536 (2016). · DOI · Paper page
  29. Reiner, D. J. et al. Glucagon-like peptide-1 receptor signaling in the lateral dorsal tegmental nucleus regulates energy balance. Neuropsychopharmacology 43, 627–637 (2018). · DOI
  30. Hayes, M. R., Skibicka, K. P. & Grill, H. J. Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation. Endocrinology 149, 4059–4068 (2008). · DOI · Paper page
  31. Suchankova, P. et al. Ghrelin receptor (GHS-R1A) antagonism suppresses both alcohol consumption and the alcohol deprivation effect in rats following long-term voluntary alcohol consumption. PLoS ONE 8, e71284 (2013). · DOI · Paper page
  32. Egecioglu, E. et al. Ghrelin increases intake of rewarding food in rodents. Addict. Biol. 15, 304–311 (2010). · DOI · Paper page
  33. Witkiewitz, K., Litten, R. Z. & Leggio, L. Advances in the science and treatment of alcohol use disorder. Sci. Adv. 5, eaax4043 (2019). · DOI · Paper page

Cited by

See all 72

Metadata

Authors
Vallöf, D., Kalafateli, A. L., & Jerlhag, E.
Venue
Translational Psychiatry
Published
2020-07-16
Volume
10
Issue
1
Pages
238-238
ISSN
2158-3188 (ISSN-L)
OpenAlex
W3042895144
Cited by
72
References
17
FWCI
2.29
Type
journal article
Language
en
Open access
gold
Licence
Funders
Arvid Carlsson Fonden (n/a)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term treatment with a glucagon-like peptide-1 receptor agonist reduces ethanol intake in male and female rats. https://app.cochat.ai/papers/10.1038/s41398-020-00923-1
The paper
Vallöf, D., Kalafateli, A. L., & Jerlhag, E. (2020). Long-term treatment with a glucagon-like peptide-1 receptor agonist reduces ethanol intake in male and female rats. Translational Psychiatry. https://doi.org/10.1038/s41398-020-00923-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.